417 F.Supp.3d 352
S.D.N.Y.2019Background
- Takeda obtained patents covering pioglitazone (the active ingredient in ACTOS) and later patents claiming combinations and methods of use; it listed those later patents in the FDA Orange Book as both drug‑product and method‑of‑use patents.
- Multiple generics filed ANDAs: some (first‑filers) submitted Paragraph IV certifications and split certifications; Teva filed only Section viii statements.
- After a Sandoz citizen petition, Takeda told the FDA in 2010 that its Orange Book listings were correct; the FDA required Paragraph IV certifications as to the Patents’ drug‑product claims, which affected Teva and other generics.
- Takeda sued generics; many suits settled and generic entry was delayed until August 17, 2012. End‑Payor Plaintiffs (EPPs) sued Takeda for monopolization under state antitrust law.
- The Second Circuit affirmed dismissal of most claims but remanded limited monopolization theory based on Teva; on remand the district court held EPPs plausibly alleged (a) Takeda’s 2010 statements were inaccurate because the drug‑product claims did not literally read on ACTOS, (b) bad faith need not be pleaded, and (c) causation under the Teva theory can extend to other generics. The court denied Takeda’s motion to dismiss.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Proper interpretation of “claims” in 21 U.S.C. § 355(b)(1) | "Claims the drug" uses plain patent meaning (a claim must read on the NDA drug); method‑of‑use language may consider infringement context | § 355(b)(1) should be read in infringement terms (a patent should be listed if its claims could be infringed by sale of the NDA drug) | Court: two meanings — plain "reads on" standard for drug/substance/product claims; infringement‑focused standard applies only to method‑of‑use claims (Apotex approach) |
| Whether Takeda’s 2010 statement to FDA was actionable anticompetitive conduct | Takeda’s listing was false because its product claims did not literally read on ACTOS; FDA relied on Takeda’s statement, causing delay | Listings reflected a reasonable interpretation of the statute; even if incorrect, any reasonable compliance is a defense and plaintiffs must plead bad faith | Court: EPPs plausibly alleged the listing was inaccurate; they need not plead bad faith at pleading stage; bad‑faith/legitimate‑interpretation is a merits/defense issue |
| Whether EPPs must allege bad faith to state monopolization from an allegedly improper Orange Book listing | Bad faith not required; unlawful listing that causes delay is anticompetitive under rule of reason | Plaintiffs must plead that the NDA‑holder acted in bad faith or objectively baselessly when listing patents | Court: refusal to require bad faith pleading; regulatory‑compliance arguments are defenses for later stages, not a pleading‑stage bar |
| Causation — does the Teva theory extend to other generics (withdrawal of Paragraph IVs and earlier market entry)? | If Takeda had truthfully listed only method‑of‑use patents, FDA would not have required Paragraph IVs and generics would have used Section viii carve‑outs to avoid litigation and enter earlier | Even if listing was inaccurate, generics would still have had to address product claims and could not avoid Paragraph IVs; no causal link | Court: EPPs plausibly alleged that the FDA’s 2010 ruling caused the challenged Paragraph IV filings and that, absent Takeda’s statements, other generics would have avoided Paragraph IVs and entered earlier; causation sufficiently pled |
Key Cases Cited
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (pleading must state plausible claim to survive 12(b)(6))
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (courts accept factual allegations as true but not legal conclusions)
- In re Actos End‑Payor Antitrust Litig., 848 F.3d 89 (2d Cir. 2017) (Second Circuit affirmed most dismissals but remanded limited Teva‑theory monopolization claim)
- Hoescht‑Roussel Pharm., Inc. v. Lehman, 109 F.3d 756 (Fed. Cir. 1997) (patent "claims" ordinarily defined by claim language; claims delimit patentee’s rights)
- Apotex, Inc. v. Thompson, 347 F.3d 1335 (Fed. Cir. 2003) (interpreting § 355 language to require product claims to "read on" the NDA drug and applying an infringement lens to method‑of‑use claims)
- Aro Mfg. Co. v. Convertible Top Replacement Co., 365 U.S. 336 (1961) (combination patent covers only the combination; individual elements not separately claimed)
- Limelight Networks, Inc. v. Akamai Techs., Inc., 572 U.S. 915 (2014) (method claims are defined by claimed combination of elements)
- Caraco Pharm. Labs., Ltd. v. Novo Nordisk, 566 U.S. 399 (2012) (discusses Orange Book listing and ANDA certification framework)
- United States v. Microsoft Corp., 253 F.3d 34 (D.C. Cir. 2001) (rule‑of‑reason framework referenced for monopolization analysis)